Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter

Journal of Molecular Medicine

Volumn 93, Issue 2, 2015, Pages 211-223

  Cheng, Pei Hsin ^a   Rao, Xiao Mei ^a   Duan, Xiaoxian ^a   Li, Xiao Feng ^a   Egger, Michael E ^a   McMasters, Kelly M ^a   Zhou, H Sam ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Autophagy; Cyclin E; Lung cancer; Oncolytic adenovirus; Virotherapy

Indexed keywords

CYCLIN E; ONCOLYTIC VIRUS;

ADENOVIRIDAE; ARTICLE; CANCER CELL; CANCER THERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DNA REPAIR; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR WEIGHT; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PROMOTER REGION; VIRUS GENE; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; AUTOPHAGY; CELL SURVIVAL; DISEASE MODEL; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; MORTALITY; MOUSE; NEOPLASMS; PATHOLOGY; REPORTER GENE; TUMOR CELL LINE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN E; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925543188     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1214-6     Document Type: Article

References (80)

1. Parker JN, Bauer DF, Cody JJ, Markert JM (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6:558–569
2. Wold WS, Toth K (2012) Chapter three–Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 115:69–92
3. Yu W, Fang H (2007) Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7:141–148
4. Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8:89–98
5. Toth K, Dhar D, Wold WS (2010) Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 10:353–368
6. Kurihara T, Brough DE, Kovesdi I, Kufe DW (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106:763–771
7. Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A, Karlsson A, Xu K, Zheng X (2013) Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. Cancer Lett 328:95–103
8. Zheng X, Rao XM, Gomez-Gutierrez JG, Hao H, McMasters KM, Zhou HS (2008) Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 82:3415–3427
9. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470–9478
10. O’Shea CC, Soria C, Bagus B, McCormick F (2005) Heat shock phenocopies E1B-55 K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8:61–74
11. Cafferata EG, Maccio DR, Lopez MV, Viale DL, Carbone C, Mazzolini G, Podhajcer OL (2009) A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models. Clin Cancer Res 15:3037–3049
12. Nettelbeck DM (2008) Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med (Berl) 86:363–377
13. Ben-Israel H, Kleinberger T (2002) Adenovirus and cell cycle control. Front Biosci 7:d1369–d1395
14. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S et al (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18:429–434
15. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R et al (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464–7472
16. Fu X, Meng F, Tao L, Jin A, Zhang X (2003) A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus. Gene Ther 10:1458–1464
17. Guo ZS, Thorne SH, Bartlett DL (2008) Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785:217–231
18. Davis JJ, Wang L, Dong F, Zhang L, Guo W, Teraishi F, Xu K, Ji L, Fang B (2006) Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther 13:720–723
19. Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q (2009) Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 89:193–199
20. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y et al (2007) Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12:52–65
21. Rao XM, Zheng X, Waigel S, Zacharias W, McMasters KM, Zhou HS (2006) Gene expression profiles of normal human lung cells affected by adenoviral E1B. Virology 350:418–428
22. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612–2624
23. Coverley D, Laman H, Laskey RA (2002) Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 4:523–528
24. Furstenthal L, Kaiser BK, Swanson C, Jackson PK (2001) Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 152:1267–1278
25. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G (1999) Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283:851–854
26. Matsumoto Y, Hayashi K, Nishida E (1999) Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 9:429–432
27. Donnellan R, Chetty R (1999) Cyclin E in human cancers. FASEB J 13:773–780
28. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222–231
29. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300
30. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE (2002) p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12:1817–1827
31. Bortner DM, Rosenberg MP (1997) Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17:453–459
32. Loeb KR, Kostner H, Firpo E, Norwood T, Tsuchiya DK, Clurman BE, Roberts JM (2005) A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8:35–47
33. Freemantle SJ, Dmitrovsky E (2010) Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) 3:1513–1518
34. Cheng PH, Rao XM, McMasters KM, Zhou HS (2013) Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E. PLoS ONE 8:e57340
35. Gomez-Gutierrez JG, Rao XM, Zhou HS, McMasters KM (2012) Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus. Virology 433:538–547
36. Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37:614–636
37. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546–554
38. Braithwaite A, Nelson C, Skulimowski A, McGovern J, Pigott D, Jenkins J (1990) Transactivation of the p53 oncogene by E1a gene products. Virology 177:595–605
39. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW et al (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723
40. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7:535–545
41. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H (2000) E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 7:177–188
42. Teodoro JG, Shore GC, Branton PE (1995) Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene 11:467–474
43. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S (1999) Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J 18:2040–2048
44. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA et al (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43
45. Garnier P, Ying W, Swanson RA (2003) Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase-1. J Neurosci 23:7967–7973
46. Luo X, Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26:417–432
47. Clark P, Dziarmaga A, Eccles M, Goodyer P (2004) Rescue of defective branching nephrogenesis in renal-coloboma syndrome by the caspase inhibitor, Z-VAD-fmk. J Am Soc Nephrol 15:299–305
48. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734
49. Rodriguez-Rocha H, Gomez-Gutierrez JG, Garcia-Garcia A, Rao XM, Chen L, McMasters KM, Zhou HS (2011) Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 416:9–15
50. Kim HJ, Lee S, Jung JU (2010) When autophagy meets viruses: a double-edged sword with functions in defense and offense. Semin Immunopathol 32:323–341
51. Chen Y, Azad MB, Gibson SB (2010) Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol 88:285–295
52. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19:5720–5728
53. Barth S, Glick D, Macleod KF (2010) Autophagy: assays and artifacts. J Pathol 221:117–124
54. Mizushima N (2004) Methods for monitoring autophagy. Int J Biochem Cell Biol 36:2491–2502
55. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T (2009) Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 452:181–197
56. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Overvatn A, Bjorkoy G, Johansen T (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282:24131–24145
57. Larsen KB, Lamark T, Overvatn A, Harneshaug I, Johansen T, Bjorkoy G (2010) A reporter cell system to monitor autophagy based on p62/SQSTM1. Autophagy 6:784–793
58. Zhang XJ, Chen S, Huang KX, Le WD (2013) Why should autophagic flux be assessed? Acta Pharmacol Sin 34:595–599
59. Wadler S, Yu B, Tan JY, Kaleya R, Rozenblit A, Makower D, Edelman M, Lane M, Hyjek E, Horwitz M (2003) Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res 9:33–43
60. Berk AJ (2006) Adenoviridae: the viruses and their replication. In: Howley DMKP (ed) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 2354–2394
61. Mullen JT, Tanabe KK (2002) Viral oncolysis. Oncologist 7:106–119
62. Kuruppu D, Tanabe KK (2005) Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 4:524–531
63. Querido E, Teodoro JG, Branton PE (1997) Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J Virol 71:3526–3533
64. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS (2004) E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 11:585–593
65. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906
66. Randow F, Munz C (2012) Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol 33:475–487
67. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E et al (2007) Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104:4089–4094
68. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H et al (2009) Uncovering growth-suppressive microRNAs in lung cancer. Clin Cancer Res 15:1177–1183
69. Barker DD, Berk AJ (1987) Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107–121
70. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC (2003) Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 63:7840–7844
71. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA (1996) Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173–1180
72. Cheng PH, Lian S, Zhao R, Rao XM, McMasters KM, Zhou HS (2013) Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virol J 10:293
73. Bett AJ, Haddara W, Prevec L, Graham FL (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 91:8802–8806
74. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518–1520
75. Kwon OJ, Kim PH, Huyn S, Wu L, Kim M, Yun CO (2010) A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16:6071–6082
76. Zheng X, Rao XM, Snodgrass CL, McMasters KM, Zhou HS (2006) Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. Cancer Gene Ther 13:572–583
77. Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, Metzker ML, Savino R, Caskey CT (2000) Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 97:1002–1007
78. Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM, Zhou HS (2003) Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 63:3073–3078
79. Huang T, Civelek AC, Zheng H, Ng CK, Duan X, Li J, Postel GC, Shen B, Li XF (2013) (18)F-Misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings. Am J Nucl Med Mol Imaging 3:142–153
80. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA et al (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99:1768–1781